Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer.
暂无分享，去创建一个
H. Lenz | B. Tran | R. Mayer | A. Ohtsu | M. Peeters | A. Zaniboni | H. Hochster | A. Falcone | R. García-Carbonero | Y. Shimada | T. Yoshino | A. Sobrero | E. Cutsem | Y. Komatsu | K. Yamazaki | F. Benedetti | K. Yoshida | L. Makris | G. Argilés | Kenichiro Yoshida